Remix Therapeutics

About:

Remix Therapeutics is a biotechnology company that is working on developing small molecule medicines.

Website: https://www.remixtx.com

Twitter/X: remixthera

Top Investors: Alexandria Venture Investments, ARCH Venture Partners, Foresite Capital, Casdin Capital, Atlas Venture

Description:

Remix Therapeutics is a biotechnology business that is working on developing small-molecule medicines to reprogram ribonucleic acid processing and cure disease in novel ways. The company's medicines aid in the identification of patterns in ribonucleic acid processing and their application to control gene expression in order to change the way genes are read from the genome, correcting, enhancing, or eliminating the gene message, allowing healthcare practitioners to address disease causes at their source.

Total Funding Amount:

$211M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2019-01-01

Founders:

Kevin Bitterman, Peter Smith

Number of Employees:

51-100

Last Funding Date:

2024-01-03

IPO Status:

Private

Industries:

© 2025 bioDAO.ai